Accreditation Information


Intended Audience 

This symposium is intended for urologists and other members of the surgical team who perform renal and prostate robotic surgery. The geographical region of the Pacific Northwest, comprising of WA, OR, ID, MT and AK, are provided for by this symposium.
 

Learning Objectives 

Upon completion of this activity, the participant should be able to: 

  • Describe the indications for robotic partial nephrectomy (RPN), robotic prostatectomy (RP), and for pelvic lymph node dissection.
  • Identify patients who are appropriate candidates for RPN, explain operating room set-up, describe proper patient positioning and potential positioning complications and recognize the variations in port placement.
  • Perform proper hilar dissection and hilar control and describe the steps for robot-assisted renorrhaphy during RPN.
  • Optimally manage patients, demonstrate proper port position for transperitoneal approach and apply strategies and techniques used by the experts.
  • Describe the role of robotics in the treatment of advanced renal cell carcinoma, identify ideal candidates for surgical debulking procedures and describe potential complications of robotic surgery in patients with advanced renal cell carcinoma.
  • Describe the technique of fluorescence imaging during RPN, recognize appropriate candidates for fluorescence imaging and identify limitations of fluorescence imaging.
  • Explain the pre-operative preparations and the post-operative care for patients undergoing RPN and identify potential issues that may preclude RPN.
  • Identify patients for retroperitoneal RPN, describe and discuss landmarks for safe retroperitoneal surgery and review contraindications for retroperitoneal RPN .
  • Describe implementation of a patient care pathway for robotic renal and robotic prostatectomy. Identify the advantages of a care pathway over conventional post operative patient care.
  • Identify indications for robotic retroperitoneal lymph node dissection (RPLND), describe the technique for robotic RPLND and review port placement for unilateral and bilateral RPLND.
  • Review and discuss the evolving role of robotic surgery for the treatment of prostate cancer, describe the indications for robotic prostatectomy (RP) and identify patients who are appropriate candidates for RP based on patient characteristics and prostate size.
  • Identify indications for simple prostatectomy, describe the technical aspects of simple prostatectomy and evaluate the differences between simple and radical prostatectomy.
  • Describe current prostate cancer risk stratification, assess the limitations of the Prostate-Specific Antigen (PSA) test as a risk stratification tool and discuss molecular staging strategies.
  • Recognize indications for extended pelvic lymph node dissection during robotic laparoscopic prostatectomy, describe port placement and technique of extended pelvic lymph node dissection (PLND) and discuss therapeutic benefit of extended PLND
  • Define continence after prostatectomy, discuss the impact of technique vs. patient characteristics on continence and describe the technical modifications to improve continence.
  • Describe patient characteristics that impact potency after RP, review optimal techniques for nerve-sparing prostatectomy and describe post-operative rehabilitation strategies to optimize potency.
  • Review and discuss measures to prevent complications during RP, identify strategies and techniques used by the experts in dealing with unexpected complications and review and discuss the role of the surgical team during complicated procedures.
     

Statement of Need 

New robotically assisted surgery methods and devices are helping to push the boundaries of medicine. By focusing on fewer incisions, more precision and more versatility with these procedures and devices, surgery is becoming safer and more efficient.

Today, robotics touches every surgical specialty, and within each specialty, it runs the gamut of procedural applications. Robotic surgery has exponentially increased in urologic oncology, specifically for radical prostatectomy and partial nephrectomy. In less than a decade, the widespread application of robotic technology to the field of urologic oncology has permanently altered the way urologists approach malignancy.

This symposium will outline improvements in surgical techniques in robotic prostatectomy and robotic partial nephrectomy. Robotic surgeons will learn tips and technical details to implement new robotic techniques in their practice. In addition, examples of the advancements in robotic surgery will be demonstrated using real-time live surgery and video presentations.
 

Accreditation Statement(s)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and the Swedish Foundation. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Physicians

Dannemiller designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Disclosures 

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE  activity must disclose all financial relationships they have with a commercial interest. 

Dannemiller Project Manager, Jennifer Hodge and NWUS facilitator Debi Johnson have no relevant financial relationships with commercial interests.  

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced. 
 

Off-label statement 

Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. 
 

Disclaimer 

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller and the Swedish Foundation. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject